Quest Diagnostics Inc vs iShares MSCI Japan ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while iShares MSCI Japan ETF trades at $93.71. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals.
| DGX | EWJ | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $96.97 |
52-Week Low | $166.42 | $71.69 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWJ, the iShares MSCI Japan ETF, trades at $92.72, down 1.94% on the day. Technical indicators are mixed, with a neutral overall signal but bullish moving averages, while key financial ratios are unavailable. The ETF provides exposure to Japanese equities but faces headwinds from yen weakness, as recent news highlights currency hedging strategies and potential government intervention to support the yen.
The outlook for EWJ is influenced by Japan's equity market performance and currency dynamics. Opportunities include diversification benefits and potential gains if the Nikkei 225 rebounds, but risks stem from yen depreciation, geopolitical tensions, and domestic economic policies. Investors should weigh currency-hedged alternatives amid ongoing volatility.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →